march.biosciences https://validator.w3.org/feed/docs/rss2.html About march.biosciences Announces Appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer march.biosciences Closes Oversubscribed $28.4 Million Series A Financing march.biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma march.biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of MB-105, First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma Contact march.biosciences Announces Oral Presentation of MB-105 Interim Phase 2 Clinical Data at American Society of Hematology Annual Meeting march.biosciences Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for MB-105 in Relapsed/Refractory CD5-Positive T-Cell Lymphoma News & Publications MB-105 Pipeline Ongoing Trial: NCT06534060 Clinical Trials march.biosciences Presents Positive Interim Clinical Data from Phase 2 Trial of MB-105 CD5 CAR-T Cell Therapy at ASH 2025 Annual Meeting Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity FCOI Policy 2023 AIM-HI Women’s Venture Competition Announced Six Semi-Finalists Cancer Focus Fund invests $4.8M into Houston-based march.biosciences The AIM-HI Accelerator Fund Recognizes, Honors, and Congratulates Its 2023 Women’s Venture Competition Top Winners march.biosciences and Cancer Focus Fund Announce $4.8 Million Investment to Support a Phase 2 Clinical Trial of Novel CAR-T Therapy for T-Cell Lymphoma Cell therapy developed by Baylor scientists shows promise as woman remains cancer-free after 5 years Anti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas Portal Innovations to call Houston its third home, with CAR-T startup march.biosciences already in the portfolio march.biosciences Welcomes Peter Olagunju to its Board of Directors Dr. Max Mamonkin awarded ASGCT 2023 Outstanding New Investigator march.biosciences and CTMC Form Strategic Alliance to Propel Innovative Cancer Cell Therapies march.biosciences recognized as a Most Promising Life Science Company by the Greater Houston Partnership at the Texas Life Science Forum. march.biosciences Awarded $13.4 Million by CPRIT to Advance Its CD5 CAR-T Therapy for T-cell Lymphoma in Phase 2 Trials Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL Chimeric Antigen Receptors for T-Cell Malignancies Privacy Policy A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies HOME